Immunoglobulin G4 (227-Proline), Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Psb103 .Gamma.4-Chain), Disulfide With Human Monoclonal Psb103 .Kappa.-Chain, Dimer
Colorectal Cancer
Explore 714 assets in Colorectal Cancer →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Shanghai Changzheng Hospital
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06930118CT.gov The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines. | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G4 (227-Proline), Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Psb103 .Gamma.4-Chain), Disulfide With Human Monoclonal Psb103 .Kappa.-Chain, Dimer (this asset) | Shanghai Changzheng Hospital | P2 | CCC · 53 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Irinotecan | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Immunoglobulin G4 (227-Proline), Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Psb103 .Gamma.4-Chain), Disulfide With Human Monoclonal Psb103 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G4 (227-Proline), Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Psb103 .Gamma.4-Chain), Disulfide With Human Monoclonal Psb103 .Kappa.-Chain, Dimer in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g4-227-proline-anti-human-programmed-cell-death-protein-1-human-monoclonal-psb103-gamma4-chain-disulfide-with-human-monoclonal-psb103-kappa-chain-dimer-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →